Emicizumab

Therapeutic indications

Emicizumab is indicated for:

Haemophilia A with factor VIII inhibitors, severe haemophilia A

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Emicizumab is indicated for routine prophylaxis of bleeding episodes in patients with:

  • haemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
  • severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: HEMLIBRA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈